Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 359

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity

Open access
Hailemichael, Yared, Johnson, Daniel H., Abdel-Wahab, Noha, Foo, Wai Chin, Bentebibel, Salah-Eddine, Daher, May, Haymaker, Cara, Wani, Khalida, Saberian, Chantal, Ogata, Dai, Kim, Sang T., Nurieva, Roza, Lazar, Alexander J., Abu-Sbeih, Hamzah, Fa'ak, Faisal, Mathew, Antony, Wang, Yinghong, Falohun, Adewunmi, Trinh, Van, Zobniw, Chrystia, Spillson, Christine, Burks, Jared K., Awiwi, Muhammad, Elsayes, Khaled, Soto, Luisa Solis, Melendez, Brenda D., Davies, Michael A., Wargo, Jennifer, Curry, Jonathan, Yee, Cassian, Lizee, Gregory, Singh, Shalini, Sharma, Padmanee, Allison, James P., Hwu, Patrick, Ekmekcioglu, Suhendan, Diab, Adi·2022·Cancer Cell

Abstract

Summary Immune checkpoint blockade (ICB) therapy frequently induces immune related adverse events. To elucidate the underlying immunobiology, we performed a deep immune analysis of intestinal, colitis, and tumor tissue from ICB-treated patients with parallel studies in preclinical models. Expression of interleukin-6 (IL-6), neutrophil and chemotactic markers was higher in colitis than in normal intestinal tissue; T helper 17 (Th17) cells were more prevalent in immune-related enterocolitis (irEC) than T helper 1 (Th1). Anti-cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA-4) induced stronger Th17 memory in colitis than anti-program death 1 (anti-PD-1). In murine models, IL-6 blockade associated with improved tumor control and a higher density of CD4+/CD8+ effector T cells, with reduced Th17, macrophages, and myeloid cells. In an experimental autoimmune encephalomyelitis (EAE) model with tumors, combined IL-6 blockade and ICB enhanced tumor rejection while simultaneously mitigating EAE symptoms versus ICB alone. IL-6 blockade with ICB could de-couple autoimmunity from antitumor immunity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2022.04.004

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 359

Metadata

Authors
Hailemichael, Y., Johnson, D. H., Abdel-Wahab, N., Foo, W. C., Bentebibel, S.-E., Daher, M., Haymaker, C., Wani, K., Saberian, C., Ogata, D., Kim, S. T., Nurieva, R., Lazar, A. J., Abu-Sbeih, H., Fa'ak, F., Mathew, A., Wang, Y., Falohun, A., Trinh, V., Zobniw, C., Spillson, C., Burks, J. K., Awiwi, M., Elsayes, K., Soto, L. S., Melendez, B. D., Davies, M. A., Wargo, J., Curry, J., Yee, C., Lizee, G., Singh, S., Sharma, P., Allison, J. P., Hwu, P., Ekmekcioglu, S., & Diab, A.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2022-05
Volume
40
Issue
5
Pages
509-523.e6
ISSN
1535-6108 (ISSN-L)
OpenAlex
W4229365571
Cited by
359
References
67
FWCI
27.10
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. https://app.cochat.ai/papers/10.1016/j.ccell.2022.04.004
The paper
Hailemichael, Y., Johnson, D. H., Abdel-Wahab, N., Foo, W. C., Bentebibel, S.-E., Daher, M., Haymaker, C., Wani, K., Saberian, C., Ogata, D., Kim, S. T., Nurieva, R., Lazar, A. J., Abu-Sbeih, H., Fa'ak, F., Mathew, A., Wang, Y., Falohun, A., Trinh, V., . . . Diab, A. (2022). Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. https://doi.org/10.1016/j.ccell.2022.04.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.